Kidney Cancer Coverage From Every Angle
Advertisement
Advertisement

Is GRP78 Expression Useful Biomarker for Clear Cell Renal Cell Carcinoma?

By: Cordi Craig
Posted: Wednesday, March 6, 2019

Despite a previous report suggesting that the neoplasmic reticulum stress marker glucose-regulated protein 78 (GRP78) may be a beneficial prognostic marker for patients with clear cell renal cell carcinoma, David W. Johnson, MD, PhD, and Glenda C. Gobe, PhD, of The University of Queensland, Brisbane, Australia, and colleagues did not find it useful as a risk-stratification marker for the disease. The study, published in PLOS One, did not report higher GRP78 expression in tumor tissue compared with paired normal renal tissue nor a strong association between GRP78 and disease aggressiveness.

“The predictive value of GRP78 expression in adipose tissue is uncertain due to the presence of conflicting findings according to methodologic approach,” the authors concluded.

This retrospective analysis focused on 267 patients who underwent nephrectomy for renal tumors. Using a software-assisted staining intensity method, the researchers measured the expression of GRP78 in archived renal tumor tissues (n = 114), adjacent non-neoplastic renal tissues (n = 68), and perinephric adipose tissues (n = 60).

Compared with paired normal renal tissue, GRP78 was not upregulated in renal tumor tissue. The authors did not observe any association between GRP78 expression and renal cell carcinoma aggressiveness. In adipose tissue, there was a poor correlation between the downregulation of GRP78 and increased probability of metastasis; with every unit increase in average grey value in GRP78 staining, there was a weakly correlating 17% increase in the odds ratio of metastasis.

Disclosure: The study authors reported no conflicts of interest.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.